2023 AWARDS
NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center
Developing novel antibody drug conjugates for the treatment
of osteosarcoma
The recognition of the potential effectiveness of DS-7300a in
the treatment of osteosarcoma has led to a phase 2 clinical
trial for patients with recurrent osteosarcoma in Europe.
Recognizing that the differential target protein expression,
between osteosarcoma and normal human tissues, was
higher for some proteins that did not have drugs already
made raised the possibility that even greater therapeutic
potential could be realized. A novel antibody drug conjugate
was created using an antibody which exists targeting CADM1
as a proof of principle. The tool compound antibody drug
candidate had numerous desirable properties, showing
dramatic effectiveness in preclinical models for the
treatment of osteosarcoma. Continued work will move this
beyond a tool compound and produce an antibody drug
conjugate, targeting CADM1 which can be administered to
patients with osteosarcoma as part of a clinical trial.
Yifei Wang, Zhongting Zhang, Wendong Zhang, Xiangjun
Tian, Rossana Lazcano, Michael Roth, Jonathan Gill, Douglas
Harrison, Zhaohui Xu, Yizheng Tu, Sylvester Jusu, Giuseppe
Longo, Xin Zhou, Jing Wang, Richard Gorlick. Targeting cell
adhesion molecule 1 (CADM1) with an antibody drug
conjugate for the treatment of osteosarcoma [abstract]. In:
Proceedings of the American Association for Cancer Research
Annual Meeting 2023; Part 1 (Regular and Invited
Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA):
AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1202.
2022 AWARDS
NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center
Recognition and optimization of antibody drug conjugates for
the treatment of osteosarcoma
With the initial proof of principle that antibody drug
conjugates may be an effective treatment strategy for
patients with osteosarcoma, review of other proteins
identified in the surfaceome profiling revealed other
opportunities. Some identified surface proteins were
associated with existing antibody drug conjugates, some
were associated with antibodies which has never been made
into drugs and others never had antibodies targeting them.
Particularly noteworthy was the expression of B7H3, also
known as CD276 as a potential surface drug. The expression
of this protein provided the opportunity that multiple
antibody drug conjugates had already been developed
targeting it. This allowed an exploration of the effect of
differing payloads on the effectiveness of the antibody drug
conjugate. This allowed a recognition that DNA damaging
agents were the most effective payloads, with DS-7300a
being the most effective drug in preclinical models for the
treatment of osteosarcoma.
Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA,
Erickson SW, Earley EJ, Mosse YP, Martinez D, Pogoriler J,
Krytska K, Patel K, Groff D, Tsang M, Ghilu S, Wang Y,
Seaman S, Feng Y, Croix BS, Gorlick R, Kurmasheva R,
Houghton PJ, Maris JM. The B7-H3-Targeting Antibody-Drug
Conjugate m276-SL-PBD Is Potently Effective Against
Pediatric Cancer Preclinical Solid Tumor Models. Clin Cancer
Res. 2021 May 15;27(10):2938-2946. doi: 10.1158/1078-
0432.CCR-20-4221. Epub 2021 Feb 22. PMID: 33619171;
PMCID: PMC8127361.
Richard Gorlick, E. Anders Kolb, Yifei Wang, Peter Houghton,
Raushan Kurmasheva, Yael Mosse, John Maris, Matthew
Tsang, David Groff, Kateryna Krytska, Xiao-Nan Li, Yuchen
Du, Jun Hasegawa, Nanae Izumi, Steven Neuhauser, Anuj
Srivastava, Tim Stearns, Vivek Philip, Emily L. Jocoy, Jeff
Chuang, Carol J. Bult, Beverly Teicher, Malcolm Smith.
Evaluation of the in vivo efficacy of the B7-H3 targeting
antibody-drug conjugate (ADC) DS7300a: A report from the
Pediatric Preclinical In Vivo Resting (PIVOT) program
[abstract]. In: Proceedings of the American Association for
Cancer Research Annual Meeting 2022; 2022 Apr 8-13.
Philadelphia (PA): AACR; Cancer Res
2022;82(12_Suppl):Abstract nr LB061.
2021 AWARDS
NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center
Our 2021 funding led to the listed publication, published in 2022
Surfaceome Targeting with Antibody Drug Conjugates
A pipeline was established to identify proteins expressed
both frequently and abundantly on the surface of
osteosarcoma cells, but not on normal tissues. It was
hypothesized that these proteins would exist related to
osteosarcoma retaining its normal property of producing
bone. A series of proteins abundantly expressed on
osteosarcoma were identified. Some of these proteins had
drugs which targeted them, specifically antibody drug
conjugates. Antibody drug conjugated work by tethering a
drug payload to an antibody which will be internalized when
it binds to the protein on the surface of a cell. As a proof of
principle we utilized an antibody drug conjugate targeting
MMP14 to show that this approach was feasible and
potentially effective.
Wang Y, Tian X, Zhang W, Zhang Z, Lazcano R, Hingorani P,
Roth ME, Gill JD, Harrison DJ, Xu Z, Jusu S, Kannan S, Wang
J, Lazar AJ, Earley EJ, Erickson SW, Gelb T, Huxley P,
Lahdenranta J, Mudd G, Kurmasheva RT, Houghton PJ, Smith
MA, Kolb EA, Gorlick R. Comprehensive Surfaceome Profiling
to Identify and Validate Novel Cell-Surface Targets in
Osteosarcoma. Mol Cancer Ther. 2022 Jun 1;21(6):903-913.
doi: 10.1158/1535-7163.MCT-21-0836. PMID: 35312779;
PMCID: PMC916771
2020 AWARDS
NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center
Our 2020 funding (together with our 2019 funding) combined into the recently final 2020
published study:
Immuno-genomic landscape of osteosarcoma
Limited clinical activity has been seen in osteosarcoma (OS) patients treated with immune
checkpoint inhibitors (ICI). To gain insights into the immunogenic potential of these tumors,
we conducted whole genome, RNA, and T-cell receptor sequencing, immunohistochemistry and
reverse phase protein array profiling (RPPA) on OS specimens from 48 pediatric and adult
patients with primary, relapsed, and metastatic OS. Median immune infiltrate level was lower
than in other tumor types where ICI are effective, with concomitant low T-cell receptor
clonalities. Neoantigen expression in OS was lacking and significantly associated with high
levels of nonsense-mediated decay (NMD). Samples with low immune infiltrate had higher number
of deleted genes while those with high immune infiltrate expressed higher levels of adaptive
resistance pathways. PARP2 expression levels were significantly negatively associated with the
immune infiltrate. Together, these data reveal multiple immunosuppressive features of OS and
suggest immunotherapeutic opportunities in OS patient.
Futreal et al. Immuno-genomic landscape of osteosarcoma
MD Anderswon Cancer Center, Houston, Texas, USA, 2020
Click here to view his Article...
2019 AWARDS
NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center
Our 2019 funding initiated the primary tools needed to undertake a major group effort examining
the limited immunogenic effects of checkpoint inhibitors (ICI) on Osteosarcoma. Dr. Gorlick's
lab at MD Anderson did multiple individual sub-studies that were part of the overall aim: to
examine if a role for a directed immunological based attack on osteosarcoma is possible.
His lab's work could be summarized:
Surfaceome Profiling of Osteosarcoma: Yifei Wang, "The Stacey Leondis Swim Across America
Research Fellow" primary project has been to identify the most abundant surface proteins on
osteosarcoma. Through comparing those to proteins known to be on normal cells the study has
identified a series of potential drug targets. They are expanding the number of osteosarcomas
profiled to refine the result.
Bar-coding as a means of understanding clonality of osteosarcoma drug resistance: Bar-coding
is a new methodology to uniquely tag every cell in an entire tumor. This method is being used
to understand which malignant cells are able to survive despite chemotherapy treatment and how
they do so. This will help guide future treatment options and improve outcomes.
Identification of approaches to target novel proteins on the surface of osteosarcoma: Dr.
Gorlick's lab has confirmed that a number of the targets identified on the surface of
osteosarcoma are abundantly expressed in virtually all osteosarcomas and to a very limited
extent on normal tissue. Some of these are not known at present to be drug targets. The lab
is making antibodies to be able to target these proteins with antibodies and cell therapy
approaches.
2018 AWARDS
NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center
Proteins on the cell surface of osteosarcoma cells can be targeted with immunotherapy.
This study focuses on identifying proteins uniquely expressed on osteosarcoma cells with the goal
developing antibody drug-conjugates and chimeric antigen receptor T-cells directed against these targets.
Utilizing mass spectrometry and RNASeq a number of potential targets have been identified and
target selection is being finalized for the creation and testing of new immunotherapies in the Gorlick Lab.
Wang Y et al. Surfaceome profiling in osteosarcoma: Identification of the candidate
immunotherapeutic target. AACR, Atlanta, GA, 2019
Click here to view his Article...
NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center
Numerous targeted agents have been developed by the pharmaceutical industry for many types of cancer.
The Gorlick lab has an extensive number of osteosarcoma mouse models that are being utilized to
pre-screen drugs that have high potential to be effective in patients with osteosarcoma.
The Gorlick lab has been genomically characterizing osteosarcoma mouse models in an effort to
match the models with specific genomic alterations with relevant targeted therapies to assess
the efficacy of “matched” therapy.
NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center
Immunotherapies, including checkpoint inhibitors, which allow patients’ immune systems to
recognize cancer cells as abnormal and clear the tumors have been effective treatments for a
number of malignancies. The Gorlick labs is establishing mouse models of osteosarcoma that have
intact immune systems in order to evaluate the efficacy of checkpoint inhibitors and other
immunotherapies in pre-clinical models, prior to bringing these agents to clinical trials in
children and adolescents.
Batko B et al. The development of a humanized xenograft murine model for osteosarcoma. CTOS, Rome, Italy, 2018
Click here to view his Article...
2017 AWARDS
NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center
This study examined the safety of giving supplemental Bone Morphogenetic Protein-2 as a
treatment to enhance the adhesion of allograft-host unions which is needed for recovery
following limb salvag surgery for osteosarcoma patients.
Dr. Gorlick reports on findings!
Click here to view his Article...
NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center
HHLA2 is a new checkpoint inhibitor (a co T cell inhibitor) in the same family as PD-L1/PD-1
and this study examines its presence in osteosarcoma. The results of this study suggested
some primary and most metastatic OS disease express this protein. This suggests this may
be a relevant immunosuppressive mechanism in the OS tumor microenvironment.
Dr. Gorlick reports on findings!
Click here to view his Article...
2016 AWARDS
NEW GRANT
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
This study examined the prognostic significance of PD-L1 expression and immune cell(s)
infiltration in osteosarcoma. It also started the investigation into the correlation
of PD-1 and/or PD-L1 expression and immune cell infiltration with 5 year EFS (event
free survival) outcomes.
Dr. Gorlick reports on findings!
Click here to view his Article...
NEW GRANT
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
This study attempted to better define the cellular origin of osteosarcoma using a mouse
model. Osteoarcoma is believed to develop from a cell that is in the process of
differentiating from a MSC (mesenchymal stem cell) to a pOB (preosteoblast).
Dr. Gorlick reports on findings!
Click here to view his Article...
2015 AWARDS
CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.
This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma
research effort in the laboratory of Dr. Richard Gorlick.
CONTINUED FUNDING
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
Targeting the insulin-like growth factor receptor – With osteosarcoma clearly associated
with normal human growth a focus of the Gorlick Laboratory has continued to be targeting this
pathway with various drugs. Two pivotal clinical trials are ongoing now testing these drugs
in sarcoma patients. A new concept targeting another member of this signaling pathway –
IGF-2R- has yielded promising results.
CONTINUED FUNDING
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
The study of GD2 directly led to a study of dinutuximab (ch14.18 antibody) by the Children’s
Oncology Group in patients with recurrent osteosarcoma which opened to patient accrual on
November 30, 2015. The study of GPNMB supported a study of glembatumumab vedotin which will
be performed by the Children’s Oncology Group with planned activation in early 2016.
NEW GRANT
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
Building upon work demonstrating the effectiveness of immune checkpoint inhibitors in the
treatment of melanoma defined by genomic complexity, which is similarly present in osteosarcoma,
the Gorlick Laboratory is initiating studies investigating the therapeutic relevance of these
drugs. Effectiveness of these agents are driven by the presence of immune infiltrates as well as
PD-1/PD-L1 expression which will be investigated with the support of the FOSTER foundation. These
studies have the potential to identify these drugs as potentially effective in osteosarcoma
driving clinical trials as previous studies have accomplished in the past.
CONTINUED FUNDING
Rachel L. Flynn, Assistant Professor, Department of Pharmacology & Experimental Therapeutics and Medicine,
Division of Hematology and Medical Oncology, Boston University School of Medicine
Probing the Alternative Lengthening of Telomeres (ALT) Pathway in Osteosarcoma
In order for a normal cell to remain a cancer cell, a number of changes need to occur with one of them being
maintaining the length of chromosomes, whose ends are called telomeres, through multiple cycles of cell division.
Although most cancers stabilize their chromosomes through activating an enzyme called telomerase, others use a
less well understood process called alternative lengthening of telomeres or ALT. The challenge with ALT is
although drugs have been developed to inactivate telomerase, drugs have not previously been discovered that
inhibit ALT. In work supported by the FOSTER foundation, the Flynn laboratory has shown that osteosarcoma uses
ALT and coupled to how these cells correct DNA errors, a therapeutic vulnerability is revealed. Furthermore
the Flynn Laboratory has discovered drugs which inhibit ALT which are needed to treat this class of tumors.
The magnitude of this drug discovery yielded a publication in the high profile journal, Science. We anticipate
with time this may yield new and improved treatments for osteosarcoma.
2014 AWARDS
CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.
This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.
CONTINUED FUNDING
Rachel L. Flynn, Assistant Professor, Department of Pharmacology & Experimental Therapeutics and Medicine, Division of Hematology and Medical Oncology, Boston University School of Medicine
Probing the Alternative Lengthening of Telomeres (ALT) Pathway in Osteosarcoma
NEW GRANT
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
Ganglioside GD2 as a Therapeutic Target for
Antibody-Mediated Therapy in Patients With Osteosarcoma
Targeting of ganglioside GD2, a glycosphingolipid on the cell surface of some tumors, with
immunotherapy has resulted in improved outcomes for patients. In the current study, the expression
pattern of GD2 was examined in osteosarcoma. Forty-four osteosarcoma samples were evaluated by
immunohistochemistry, GD2 was expressed on all 44 osteosarcoma samples. Ganglioside GD2 is highly
expressed on osteosarcomas. Clinical trials are needed to assess the efficacy of targeting GD2 in
patients with osteosarcoma.
NEW GRANT
We have co sponsored this study with The Barbara Epstein Foundation and Swim Across America:
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
Targeting Glycoprotein NMB with Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma
Targeting glycoprotein non-metastatic b (GPNMB) with the antibody-drug conjugate glembatumumab
vedotin has demonstrated activity in patients with melanoma and breast cancer. The potential utility
of targeting GPNMB in osteosarcoma was explored. All osteosarcoma cell lines demonstrated surface
GPNMB expression. Glembatumumab induced cytotoxic effects in 74% (14/19) of osteosarcoma cell lines,
and GPNMB protein levels correlated with glembatumumab in vitro cytotoxicity (r= -0.46, p= 0.04).
GPNMB is expressed in osteosarcoma and targeting GPNMB with the antibody-drug conjugate glembatumumab
vedotin demonstrates osteosarcoma cytotoxic activity. Clinical trials are indicated to assess the
efficacy of targeting GPNMB in patients with osteosarcoma.
2013 AWARDS
Our supported studies for targeted therapies are entering clinical trials
NEW GRANT
Rachel L. Flynn, Assistant Professor, Department of Pharmacology & Experimental Therapeutics and Medicine,
Division of Hematology and Medical Oncology, Boston University School of Medicine
Probing the Alternative Lengthening of Telomeres (ALT) Pathway in Osteosarcoma
CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.
This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.
CONTINUED FUNDING
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
New Clinical Trials for IGF1R Antibodies for the Treatment of Osteosarcoma
Our efforts have been instrumental in defining IGF-1R
antibodies as relevant to the treatment of osteosarcoma. These studies
along with others continue to drive the clinical development of IGF-1R
antibodies. A trial is ongoing in Pediatric Oncology at the Memorial
Sloan-Kettering Cancer Center investigating an IGF-1R antibody
combination. A major study is being developed by the Children’s Oncology
Group testing the effectiveness of IGF-1R antibody and it is anticipated
patients will be able to enroll on this study shortly.
New
Clinical Trial for Arginine depletion therapy at MD Anderson Cancer
Center for osteosarcoma
Argininosuccinate Synthetase Protein and Correlation with Novel
Therapeutic ADI-PEG20 in Osteosarcoma
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
The amino acid arginine is involved in protein synthesis and tumor
metabolism and is essential for the growth of human cancer cells.
Pegylated arginine deaminase (ADI-PEG20) is a novel therapy that lowers
extracellular arginine levels and has shown evidence of clinical
efficacy and low toxicity in patients with tumors lacking
argininosuccinate synthetase (ASSl) protein expression.
NEW GRANT
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx,
New York
Targeted Therapy: CD47 as a Therapeutic Target for Osteosarcoma.
CD47 a marker expressed on the surface of numerous tumors has been
identified as a potential therapeutic target in a variety of
malignancies. Based on those observations, initial studies were
undertaken in osteosarcoma demonstrating the proteins frequent surface
expression. Further studies are being supported investigating whether
approaches targeting CD47 may be effective in the treatment of
osteosarcoma.
2012 AWARDS
New Clinical Trial for
Arginine depletion therapy at MD Anderson Cancer Center for
Osteosarcoma
Argininosuccinate Synthetase Protein and Correlation with Novel
Therapeutic ADI-PEG20 in Osteosarcoma
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx,
New York
The
amino acid arginine is involved in protein synthesis and tumor
metabolism and is essential for the growth of human cancer cells.
Pegylated arginine deaminase (ADI-PEG20) is a novel therapy that lowers
extracellular arginine levels and has shown evidence of clinical
efficacy and low toxicity in patients with tumors lacking
argininosuccinate synthetase (ASSl) protein expression.
CONTINUED FUNDING
The Osteosarcoma Genome Project
Marc Ladanyi, M.D., Paul Meyers, M.D. John Healey, M.D. - Memorial Sloan
Kettering Cancer Center-New York, New York
Awarded in 2010: Osteosarcoma is not currently a focus of federally
supported cancer genomics efforts such as The Cancer Genome Atlas. Our
study will comprehensively screen the genome of both pediatric and adult
Osteosarcomas for cancer causing mutations. Genomic technologies have
advanced rapidly in recent years, making it possible to completely
screen all genes in a given tumor sample for mutations. Screening of
even a small number of samples of a given cancer type can yield
important discoveries. The uniqueness of this study is that the analysis
is coming from patients tumors at different stages of their disease i.e.
not only biopsies.
CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.
This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.
2011 AWARDS
NEW GRANT
Variable Expression of Argininosuccinate Synthetase Protein and
Correlation with Novel Therapeutic ADI-PEG20 in Osteosarcoma
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
The amino acid arginine is involved in protein synthesis and tumor
metabolism and is essential for the growth of human cancer cells.
Pegylated arginine deaminase (ADI-PEG20) is a novel therapy that
lowers extracellular arginine levels and has shown evidence of
clinical efficacy and low toxicity in patients with tumors lacking
argininosuccinate synthetase (ASSl) protein expression. Previous
studies have demonstrated the effectiveness of ADI-PEG20 in cancer
cell lines with diminished or absent ASS1 protein including melanoma
and hepatocellular carcinoma. Breast cancer and lung cancer cell
lines, both of which frequently maintain strongly positive ASS1
protein expression, continued to proliferate in the presence of
ADI-PEG20. ADI-PEG20 sensitivity has not been previously evaluated in
osteosarcoma.
CONTINUED FUNDING
The Osteosarcoma Genome Project
Marc Ladanyi, M.D., Paul Meyers, M.D. John Healey, M.D. - Memorial
Sloan Kettering Cancer Center-New York, New York
Awarded in 2010: Osteosarcoma is not currently a focus of federally
supported cancer genomics efforts such as The Cancer Genome Atlas. Our
study will
comprehensively screen the genome of both pediatric and adult Osteosarcomas for
cancer causing mutations. Genomic technologies have advanced rapidly
in recent years,
making it possible to completely screen all genes in a given tumor
sample for mutations.
Screening of even a small number of samples of a given cancer type can
yield important discoveries.
The uniqueness of this study is that the analysis is coming from
patients tumors at different
stages of their disease i.e. not only biopsies.
CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.
This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.
2010 AWARDS
NEW GRANT
The Osteosarcoma Genome Project
Marc Ladanyi, M.D., Paul Meyers, M.D. John Healey, M.D. - Memorial
Sloan Kettering Cancer Center-New York, New York Awarded in 2010: Osteosarcoma is not currently a focus of
federally supported cancer genomics efforts such as The Cancer Genome
Atlas or the TARGET initiative. Our study will comprehensively screen
the genome of both pediatric and adult Osteosarcomas for cancer causing
mutations. Genomic technologies have advanced rapidly in recent years,
making it possible to completely screen all genes in a given tumor
sample for mutations. Screening of even a small number of samples of a
given cancer type can yield important discoveries.
CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.
This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.
Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory
Dr. Alex Chou- Pediatrics-Memorial Sloan Kettering Cancer Center-New
York, New York
CONTINUED FUNDING
awarded in 2009: This study of IGF-1R (insulin like growth factor), a
highly active molecular pathway for osteosarcoma continues.
CONTINUED FUNDING
awarded in 2009: We have co sponsored with the
Stavros Niarchos Foundation
a study being performed by Dr. Jennifer Perry at the Dana Farber Cancer
Institute, Boston, Massachusetts. Her experiments will attempt to
identify new pathways that are required for the viability and
proliferation of p53/pRb-null osteosarcoma cells.
CONTINUED FUNDING
awarded in 2009: This study is being performed by Dr. Erik Sampson at
The University of Rochester, Rochester, New York. Dr. Sampson’s study is
a preclinical evaluation of the c-Met inhibitor MK-8033 for the
treatment of human osteosarcoma.
2009 AWARDS
NEW GRANT
The Swim Across America Foundation of Nassau and Suffolk
has created the
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”,
Bronx, New York. This annual support will be given to the osteosarcoma
research laboratory of Dr. Richard Gorlick in Stacey’s memory.
Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory
Dr. Alex Chou- Pediatrics-Memorial Sloan Kettering Cancer Center-New
York, New York
CONTINUED FUNDING
awarded in 2009: This study of IGF-1R (insulin like growth factor), a
highly active molecular pathway for osteosarcoma continues.
NEW GRANT awarded in 2009: We have co sponsored
with the
Stavros Niarchos Foundation a study being performed by Dr. Jennifer
Perry at the Dana Farber Cancer Institute, Boston, Massachusetts. Her
experiments will attempt to identify new pathways that are required for
the viability and proliferation of p53/pRb-null osteosarcoma cells.
NEW GRANT awarded in 2009: This study is being
performed by Dr. Erik Sampson at The University of Rochester, Rochester,
New York. Dr. Sampson’s study is a preclinical evaluation of the c-Met
inhibitor MK-8033 for the treatment of human osteosarcoma.
2008
AWARDS
CONTINUED FUNDING Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory Dr. Alex Chou- Pediatrics-Memorial
Sloan Kettering Cancer Center-New York, New York
awarded in 2008: We have been co-funding with the
Swim
Across America Foundation of Nassau and Suffolk for the past 3 years, a
study of IGF-1R (insulin like growth factor), a highly active molecular
pathway for osteosarcoma. We are very pleased to state that this study
provided much of the basic science research needed for the initiation of
a Phase II clinical trial of IGF-1R targeted therapy in osteosarcoma
patients. A Phase III trial is currently in development based on
promising results from the Phase II study. This is the first time that a
targeted therapy for osteosarcoma will enter a Phase III clinical trial!
NEW GRANT
awarded in 2008: We have co-sponsored with the
Liddy Shriver
Sarcoma Initiative a study at The University of Texas -MD Anderson
Cancer Center, Houston, Texas for Dr. Nadezhda Koshkina's study of the
role of CIP4 in osteosarcoma metastases.
NEW GRANT
awarded in 2008:
We have co sponsored with the
Stavros Niarchos Foundation
a study being performed by Dr. Anders Kolb at the AI Dupont Hospital for Children. His experiments will examine the effect of
a monoclonal antibody against IGF-1R in a xenograft model. This work
seeks to identify the potential downstream targets in responsive
tumors. Dr. Kolb proposes to use gene array in a series of responsive
and non-responsive tumors to determine the targets involved. This will
allow optimization of patient selection for this therapy as well as the
design of more effective treatment combinations.
2007
AWARDS Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory Dr. Alex Chou- Pediatrics-Memorial
Sloan Kettering Cancer Center-New York, New York
NEW GRANT
awarded in 2007: The study is attempting to define which pathway(s) is used by osteosarcoma. Additionally it will analyze and
prioritize which small molecule pathway inhibitor(s) could be used to
treat osteosarcoma.
Peter Menges - Foster Board Member Robert Panariello - Professional
Athletic Performance Center, Garden City, New York
CONTINUED FUNDING
in 2007 for the physical conditioning and positive
self image program designed especially for children upon completion of
or during treatment for any pediatric cancer. Mark Weinblatt, MD,
Pediatric Oncology Medical Director at Winthrop-University Hospital's
Cancer Center for Kids referred the first two groups of participants in
2006.
CLICK HERE for News Article:
Professor Wei Zhu, PHD, New York-Applied Math and Statistics Yue
Zhang-PHD- Applied Math and Statistics Renyuan Luo-Graduate Student-Applied Math and Statistics SUNY at
Stony Brook-New York
CONTINUED FUNDING
in 2007 for the development of a
"translational tool" (computer program) that can predict response to chemotherapy, for
Osteosarcoma, prior to treatment using microarray genetic signatures.
2006 AWARDS Chand Khanna- DVM, PhD, National
Cancer Institute, Bethesda, Maryland -
Research & Tumor Metastasis Section - Pediatric Oncology Branch
NEW GRANT
for the testing of a "targeted" (limited toxicity) agent for osteosarcoma in an animal study for the National Institute of Health -
Comparative Oncology - Pediatrics.
Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory
NEW GRANT
awarded
for the upgrade of the genetic sequencer at the pediatric sarcoma lab.
This upgrade is a four fold improvement in the labs SAGE sequencing
capabilities.
CLICK HERE for Thank You Letter
Peter Menges - Foster Board Member - Garden City, New York
NEW GRANT
in 2006 for the "trial" of a physical conditioning and positive self
image program for children upon completion of therapy, of any pediatric
cancer.
CLICK HERE for News Article
Wei Zhu, PHD, SUNY at Stony Brook-New York, New York-Applied Math and
Statistics
CONTINUED FUNDING
in 2006
to Dr. Zhu for the development of
a mathematical algorithm for osteosarcoma. This program will attempt to
correlate SAGE data to DNA microarray data to patient status.
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
All from SUNY at Stony Brook-New York
CONTINUED FUNDING
in 2006 for the development of a “translational tool”
(computer program) that can predict response to chemotherapy, for Osteosarcoma,
prior to treatment using microarray genetic signatures.
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
SUNY at Stony Brook-New York
CONTINUED FUNDING
in 2006 for the analysis of metastatic osteosarcoma datasets using
microarray and SAGE signatures.
2005 AWARDS
Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory
NEW GRANT
awarded
for the compiling of microarray and SAGE datasets for metastatic
Osteosarcoma.
Wei Zhu, PHD, SUNY at Stony Brook-New York, New York-Applied Math and
Statistics
CONTINUED FUNDING
in 2005
to Dr. Zhu for the development of
a mathematical algorithm for osteosarcoma. This program will attempt to
correlate SAGE data to DNA microarray data to patient status.
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
Neophytos Neophytou , Ph.D. Student, Department of Computer Science
All from SUNY at Stony Brook-New York
CONTINUED FUNDING
in 2005 for the development of a “translational tool”
(computer program) that can predict response to chemotherapy, for Osteosarcoma,
prior to treatment using microarray genetic signatures.
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
SUNY at Stony Brook-New York
NEW GRANT
awarded
for the analysis of metastatic osteosarcoma datasets using
microarray and SAGE signatures.
2004 AWARDS
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics Neophytos Neophytou ,
Ph.D. Student, Department of Computer Science
All from SUNY at Stony Brook
NEW GRANT
awarded for the development of a “translational tool”
(computer program) that can predict response to chemotherapy, for Osteosarcoma, prior to treatment using microarray genetic
signatures.
Wei Zhu, PHD, SUNY at Stony Brook, New York-Applied Math and Statistics
CONTINUED FUNDING
in 2004 to Dr. Zhu for the development of a mathematical algorithm for osteosarcoma. This program will attempt to correlate SAGE data
to DNA microarray data to patient status.
PHOTO UPDATE! -- Wei Zhu
Group Click here to view the photo...
2003 AWARD
Wei Zhu, PHD, SUNY at Stony Brook, New York-Applied Math and Statistics
NEW GRANT
awarded to Dr. Zhu for the development of a mathematical algorithm for osteosarcoma. This program will attempt to correlate SAGE data
to DNA microarray data to patient status.
PHOTO UPDATE! -- Wei Zhu, PHD - SUNY at Stony Brook Click here to view the photo...
2002 AWARD
Dr. Richard Gorlick of The Sloan Kettering Memorial Cancer Center,
New York-The Pediatric Sarcoma Research Laboratory
NEW GRANT
awarded to Dr. Gorlick for the purchase of an Applied Biosystem Inc.-ABI
Prism 3100 Genetic Analyzer. This new device will enable the
laboratory to expedite and further analyze different genetic
expressions and possible targets for additional research.
NEWS UPDATE! -- Dr. Gorlick reports on findings!
Click here to view his letter...
|